These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 1650219)
1. Bemoradan--a novel inhibitor of the rolipram-insensitive cyclic AMP phosphodiesterase from canine heart tissue. Moore JB; Combs DW; Tobia AJ Biochem Pharmacol; 1991 Jul; 42(3):679-83. PubMed ID: 1650219 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. Souness JE; Hassall GA; Parrott DP Biochem Pharmacol; 1992 Sep; 44(5):857-66. PubMed ID: 1326964 [TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase inhibition in ventricular cardiomyocytes from guinea-pig hearts. Bethke T; Meyer W; Schmitz W; Scholz H; Stein B; Thomas K; Wenzlaff H Br J Pharmacol; 1992 Sep; 107(1):127-33. PubMed ID: 1384905 [TBL] [Abstract][Full Text] [Related]
4. Characterization of indolidan- and rolipram-sensitive cyclic nucleotide phosphodiesterases in canine and human cardiac microsomal fractions. Lugnier C; Muller B; Le Bec A; Beaudry C; Rousseau E J Pharmacol Exp Ther; 1993 Jun; 265(3):1142-51. PubMed ID: 8389853 [TBL] [Abstract][Full Text] [Related]
6. Comparison of cyclic nucleotide phosphodiesterase isoenzymes in rat and rabbit ventricular myocardium: positive inotropic and phosphodiesterase inhibitory effects of Org 30029, milrinone and rolipram. Shahid M; Nicholson CD Naunyn Schmiedebergs Arch Pharmacol; 1990 Dec; 342(6):698-705. PubMed ID: 1710786 [TBL] [Abstract][Full Text] [Related]
8. Proteolysis of cyclic AMP phosphodiesterase-II attenuates its ability to be inhibited by compounds which exert positive inotropic actions in cardiac tissue. Price B; Pyne NJ; Houslay MD Biochem Pharmacol; 1987 Dec; 36(23):4047-54. PubMed ID: 2825712 [TBL] [Abstract][Full Text] [Related]
9. Possible role of cyclic AMP phosphodiesterases in the actions of ibudilast on eosinophil thromboxane generation and airways smooth muscle tone. Souness JE; Villamil ME; Scott LC; Tomkinson A; Giembycz MA; Raeburn D Br J Pharmacol; 1994 Apr; 111(4):1081-8. PubMed ID: 8032594 [TBL] [Abstract][Full Text] [Related]
10. Cyclic nucleotide phosphodiesterases from frog atrial fibers: isolation and drug sensitivities. Lugnier C; Gauthier C; Le Bec A; Soustre H Am J Physiol; 1992 Mar; 262(3 Pt 2):H654-60. PubMed ID: 1373036 [TBL] [Abstract][Full Text] [Related]
11. Role of phosphodiesterase isoenzymes in regulating intracellular cyclic AMP in adenosine-stimulated smooth muscle cells. Xiong Y; Westhead EW; Slakey LL Biochem J; 1995 Jan; 305 ( Pt 2)(Pt 2):627-33. PubMed ID: 7832782 [TBL] [Abstract][Full Text] [Related]
12. (Imidazolylphenyl)pyrrol-2-one inhibitors of cardiac cAMP phosphodiesterase. Lampe JW; Chou YL; Hanna RG; Di Meo SV; Erhardt PW; Hagedorn AA; Ingebretsen WR; Cantor E J Med Chem; 1993 Apr; 36(8):1041-7. PubMed ID: 8386770 [TBL] [Abstract][Full Text] [Related]
13. Biochemical and pharmacological characterization of cyclic nucleotide phosphodiesterase in airway epithelium. Rousseau E; Gagnon J; Lugnier C Mol Cell Biochem; 1994 Nov; 140(2):171-5. PubMed ID: 7898488 [TBL] [Abstract][Full Text] [Related]
14. Relaxation of guinea-pig trachea by cyclic AMP phosphodiesterase inhibitors and their enhancement by sodium nitroprusside. Turner NC; Lamb J; Worby A; Murray KJ Br J Pharmacol; 1994 Apr; 111(4):1047-52. PubMed ID: 8032589 [TBL] [Abstract][Full Text] [Related]
15. Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations. von der Leyen H; Mende U; Meyer W; Neumann J; Nose M; Schmitz W; Scholz H; Starbatty J; Stein B; Wenzlaff H Naunyn Schmiedebergs Arch Pharmacol; 1991 Jul; 344(1):90-100. PubMed ID: 1723153 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds. de Cheffoy de Courcelles D; de Loore K; Freyne E; Janssen PA J Pharmacol Exp Ther; 1992 Oct; 263(1):6-14. PubMed ID: 1328613 [TBL] [Abstract][Full Text] [Related]
18. Differential sensitivity to cardiotonic drugs of cyclic AMP phosphodiesterases isolated from canine ventricular and sinoatrial-enriched tissues. Komas N; Lugnier C; Le Bec A; Serradeil-Le Gal C; Barthélémy G; Stoclet JC J Cardiovasc Pharmacol; 1989 Aug; 14(2):213-20. PubMed ID: 2476593 [TBL] [Abstract][Full Text] [Related]
19. Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram. Souness JE; Maslen C; Webber S; Foster M; Raeburn D; Palfreyman MN; Ashton MJ; Karlsson JA Br J Pharmacol; 1995 May; 115(1):39-46. PubMed ID: 7647982 [TBL] [Abstract][Full Text] [Related]
20. Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility. Weishaar RE; Kobylarz-Singer DC; Steffen RP; Kaplan HR Circ Res; 1987 Oct; 61(4):539-47. PubMed ID: 2820608 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]